News and Trends 23 Jun 2023
New disease characteristic seen as NMD Pharma reports Charcot-Marie-Tooth results
NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, has presented results from ESTABLISH1, an observational study of neuromuscular function in patients with the inherited neurological conditions Charcot-Marie-Tooth (CMT) types 1 and 2. The results were revealed in a poster presentation at the Peripheral Nerve Society Annual […]